Stocks · News reference
Galmed Pharmaceuticals Announces Breakthrough Development Of New Aramchol-Based Lipid Nanoparticles Formulation For Targeted Delivery To The Heart
Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's biodistribution
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 16, 2026, 11:35 AM
- Checked
- Jul 16, 2026, 11:35 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Read original at benzingaGalmed Pharma’s Subsidiary Colospan Completes Feasibility Study Supporting Development Of Intraoperative Colon Tissue Quality Assessment Platform
The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in Israel. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of
Read original at benzingaTrading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
Read original at benzinga